Book a Call
MDside
Book a Call

Kisspeptin: real science, studied in a different molecule

  • MDside
  • October 9, 2026

Key points

  • Kisspeptin-54 triggered oocyte maturation in IVF, with 23% clinical pregnancy in the first study (53 women) [1].
  • In women at high risk of ovarian hyperstimulation, there was no moderate or severe OHSS (60 women, open label) [2].
  • In hypoactive sexual desire, studies used a single IV infusion and mostly measured functional MRI [4][5].
  • The form nominated for US compounding is kisspeptin-10, which FDA keeps in Category 2 [6].

US status (October 2026): Kisspeptin-10 remains in Category 2 of FDA’s 503A bulk substance list as updated May 2026 [6]. See the peptide status tracker.

Kisspeptin is the switch for the reproductive axis

Kisspeptin triggers GnRH release in the hypothalamus, and with it the whole reproductive axis. A group at Imperial College London has produced much of the human evidence, published in leading journals [1][2][3]. That is why patients and vendors cite it. The question for you is which molecule, which route and which outcome those studies used.

Fertility holds the strongest data

In 2014, a single subcutaneous injection of kisspeptin-54 triggered oocyte maturation in women undergoing IVF. In that first study (53 women), the clinical pregnancy rate was 23% [1].

In 2015, in 60 women at high risk of ovarian hyperstimulation syndrome, no moderate or severe OHSS was observed, and the live-birth rate per transfer was 45%. It was an open-label phase 2 trial, randomized only between doses and without a control group [2].

The sexual desire studies measured brain imaging

In 29 healthy men, kisspeptin modified brain processing of sexual and emotional stimuli [3]. In women with hypoactive sexual desire (32 participants), an IV infusion of kisspeptin-54 changed brain activity on functional MRI [4]. In men with hypoactive sexual desire (32 participants), it was associated with up to 56% more penile tumescence than placebo [5].

  • 23%: clinical pregnancy in the first IVF study (53 women) [1]
  • 0: cases of moderate or severe OHSS in 60 high-risk women [2]
  • 32: participants in each hypoactive-desire study [4][5]

Three differences separate the studies from the market

  1. The molecule. The studies used kisspeptin-54. The form nominated for US compounding is kisspeptin-10, a shorter isoform [6].
  2. Route and setting. The studies gave single infusions or injections, in IVF units or trial centers, with monitoring.
  3. The outcomes. For sexual desire, the main results are functional MRI changes, not sustained clinical efficacy [4][5].

FDA keeps kisspeptin-10 in Category 2 of its 503A list and explains that “FDA has no, or only limited, safety-related information for the proposed routes of administration” [6][7]. The July 2026 advisory committee did not change that, as covered in What FDA said about peptides in July 2026.

What this means for you

Kisspeptin has some of the best human science of any peptide. That science is for kisspeptin-54, in single doses and controlled settings [1][2][4][5]. Extrapolating it to repeated use of kisspeptin-10 is not supported by those studies.

When a patient cites a kisspeptin study, ask three questions: which isoform, which route and schedule, and which outcome. If the answers are kisspeptin-54, a single monitored dose and a brain scan, the study does not describe the product in front of you.

If a patient brings you a kisspeptin-10 vial, the trial data do not describe what is in it, and a research use only label does not make it a lawful source. For PT-141 (bremelanotide), which FDA approved as Vyleesi, see PT-141 status. For how MDside reviews peptide requests, see peptide programs.

References

  1. Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-77. PMID 25036713. Link
  2. Abbara A, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100(9):3322-31. PMID 26192876. Link
  3. Comninos AN, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. PMID 28112678. Link
  4. Thurston L, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PMID 36287566. Link
  5. Mills EG, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2254313. PMID 36735255. Link
  6. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1 to 3). Updated 14 May 2026. Link
  7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.

Share this article with a friend

Medical direction. Victor D. Cruz, MD, Systems Medical Director, licensed in Florida (ME117105) and New York, directs structure, corporate practice of medicine, delegation and good faith exams. This states who carries clinical responsibility for this subject area. It is not a page-level review: pages that have been reviewed name the reviewer and show the date. How this site is written and checked.